Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA Approves Abaxis’ New C-Reactive Protein Assay
The company claims that as a result of this approval, US healthcare professionals can conduct on-site chemistry analysis in less than 12 minutes for many types of conditions,
The company claims that as a result of this approval, US healthcare professionals can conduct on-site chemistry analysis in less than 12 minutes for many types of conditions,
The company claims that the 12-gene advanced diagnostic test is clinically validated to predict individual recurrence risk in stage II colon cancer patients following surgery, as reported at
Under the terms of the transaction, Martek will pay consideration of $200m, subject to working capital adjustments, of which $120m will be paid from its current cash reserves
As a result, the scientific/technical review procedure commenced on 21 January 2010. Xiaflex is a biologic for the treatment of dupuytren’s contracture. Based on the completion of the
Reportedly, ChemPoint will manage the complete order and fulfillment process for SolVin’s Ixan SGA-1 PVDC resin, from order placement to delivery to technical support. Diego Lancksweert, business manager
The MiniFiler kit, designed to obtain DNA results from compromised or degraded samples, has utility in a wide range of investigations, including cold cases, missing person cases, exonerations
Dr Whaley Bishnoi and her team specialise in tunable nanoparticle sensors that look at local pH on an intercellular level. They use the Zetasizer Nano to measure the
On January 15, 2010, pursuant to the Hatch-Waxman Act, Watson notified Endo’s partners, Teikoku Seiyaku Co and Teikoku Pharma USA, that its ANDA requesting approval from the FDA
Reportedly, Maik Jornitz has been an active member of the PDA since 1994, holding a number of voluntary functions. He was also member of the task forces that
The technology complements MorphoSys’s existing production platforms. It could offer advantages with regard to the production of novel antigens, which have proven difficult to produce with conventional expression